These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25041869)

  • 1. Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.
    López-Farré AJ; Rodriguez-Sierra P; Modrego J; Segura A; Martín-Palacios N; Saiz AM; Zamorano-León JJ; Duarte J; Serrano J; Moñux G
    Br J Clin Pharmacol; 2014 Dec; 78(6):1366-77. PubMed ID: 25041869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa.
    Zekri-Nechar K; Zamorano-León JJ; Reche C; Giner M; López-de-Andrés A; Jiménez-García R; López-Farré AJ; Martínez-Martínez CH
    Dis Markers; 2022; 2022():1118195. PubMed ID: 36438904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.
    Pham PT; Fukuda D; Yagi S; Kusunose K; Yamada H; Soeki T; Shimabukuro M; Sata M
    Sci Rep; 2019 Aug; 9(1):11206. PubMed ID: 31371788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.
    Moñux G; Zamorano-León JJ; Marqués P; Sopeña B; García-García JM; Laich de Koller G; Calvo-Rico B; García-Fernandez MA; Serrano J; López-Farré A
    Br J Clin Pharmacol; 2017 Dec; 83(12):2661-2670. PubMed ID: 28735510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa Inhibition by Rivaroxaban Modified Mitochondrial-Associated Proteins in Human Abdominal Aortic Aneurysms.
    Zamorano-Leon JJ; Serna-Soto M; Moñux G; Freixer G; Zekri-Nechar K; Cabrero-Fernandez M; Segura A; Gonzalez-Cantalapiedra A; Serrano J; Farré AL
    Ann Vasc Surg; 2020 Aug; 67():482-489. PubMed ID: 32173474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.
    Hara T; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Eur J Pharmacol; 2018 Feb; 820():222-228. PubMed ID: 29269019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
    Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
    Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
    Petzold T; Thienel M; Dannenberg L; Mourikis P; Helten C; Ayhan A; M'Pembele R; Achilles A; Trojovky K; Konsek D; Zhang Z; Regenauer R; Pircher J; Ehrlich A; Lüsebrink E; Nicolai L; Stocker TJ; Brandl R; Röschenthaler F; Strecker J; Saleh I; Spannagl M; Mayr CH; Schiller HB; Jung C; Gerdes N; Hoffmann T; Levkau B; Hohlfeld T; Zeus T; Schulz C; Kelm M; Polzin A
    Circ Res; 2020 Feb; 126(4):486-500. PubMed ID: 31859592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
    Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
    Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
    Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U
    Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
    Flierl U; Fraccarollo D; Micka J; Bauersachs J; Schäfer A
    Pharmacol Res; 2013 Aug; 74():49-55. PubMed ID: 23714416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in fatty acid metabolism and sirtuin signaling characterize early type-2 diabetic hearts of fructose-fed rats.
    Lou PH; Lucchinetti E; Scott KY; Huang Y; Gandhi M; Hersberger M; Clanachan AS; Lemieux H; Zaugg M
    Physiol Rep; 2017 Aug; 5(16):. PubMed ID: 28830979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
    Delbeck M; Nickel KF; Perzborn E; Ellinghaus P; Strassburger J; Kast R; Laux V; Schäfer S; Schermuly RT; von Degenfeld G
    Cardiovasc Res; 2011 Oct; 92(1):159-68. PubMed ID: 21676958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demeanor of rivaroxaban in activated/inactivated FXa.
    Seki K; Mizuno Y; Sakashita T; Nakano S; Tanno J; Okazaki Y; Muramatsu T; Nishimura S; Senbonmatsu T
    J Pharmacol Sci; 2017 Mar; 133(3):156-161. PubMed ID: 28314697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
    Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.
    Wagner NM; Dressel T; Schäfer K; Konstantinides S
    Thromb Res; 2012 Nov; 130(5):793-8. PubMed ID: 22281071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
    Bukowska A; Zacharias I; Weinert S; Skopp K; Hartmann C; Huth C; Goette A
    Eur J Pharmacol; 2013 Oct; 718(1-3):114-23. PubMed ID: 24041930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E; Kubitza D; Misselwitz F
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.